Articles with "neprilysin inhibitor" as a keyword



Photo from wikipedia

Angiotensin receptor‐neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime

Sign Up to like & get
recommendations!
Published in 2022 at "ESC Heart Failure"

DOI: 10.1002/ehf2.13963

Abstract: Duchenne muscular dystrophy (DMD) is an X‐linked recessive neuromuscular disorder, characterized by significant long‐term cardiac involvement. Dilated cardiomyopathy (DCM) is the main cause of death in DMD, and angiotensin‐converting enzyme inhibitors (ACEi) and beta‐blockers (BB)… read more here.

Keywords: angiotensin; neprilysin inhibitor; receptor neprilysin; angiotensin receptor ... See more keywords
Photo from wikipedia

Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.

Sign Up to like & get
recommendations!
Published in 2017 at "International journal of cardiology"

DOI: 10.1016/j.ijcard.2016.06.083

Abstract: Sacubritil∗valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart… read more here.

Keywords: new class; angiotensin receptor; receptor neprilysin; neprilysin inhibitor ... See more keywords
Photo from wikipedia

P5436Angiotensin receptor-neprilysin inhibitor preserved cardiac function via improving angiogenetic ability in mice model of atherosclerosis

Sign Up to like & get
recommendations!
Published in 2019 at "European Heart Journal"

DOI: 10.1093/eurheartj/ehz746.0392

Abstract: Angiotensin receptor-neprilysin inhibitor (ARNI) increases natriuretic peptide and improves heart failure. We previously reported that ARNI has the effects of suppression of myocardial hypertrophy and fibrosis in addition to reduction of afterload by natriuretic effect.… read more here.

Keywords: arni; neprilysin inhibitor; group; ctl group ... See more keywords
Photo from wikipedia

Post-Discharge Initiation of Angiotensin Receptor-Neprilysin Inhibitor in an Inotrope-Dependent Patient in the Outpatient Setting: A Case Report

Sign Up to like & get
recommendations!
Published in 2020 at "Hospital Pharmacy"

DOI: 10.1177/0018578720946756

Abstract: Purpose: Angiotensin receptor-neprilysin inhibitor (ARNI) therapy has been reported to be initiated in patients on vasoactive medications during acute decompensated heart failure. However, there is... read more here.

Keywords: angiotensin receptor; receptor neprilysin; neprilysin inhibitor;
Photo from wikipedia

The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022

Sign Up to like & get
recommendations!
Published in 2022 at "Frontiers in Cardiovascular Medicine"

DOI: 10.3389/fcvm.2022.899235

Abstract: Cardiovascular disease (CVD) has become a huge challenge for the global public health system due to its high morbidity, mortality and severe economic burden. In recent years, angiotensin receptor neprilysin inhibitor (ARNI), a new class… read more here.

Keywords: receptor neprilysin; medicine; angiotensin receptor; neprilysin inhibitor ... See more keywords
Photo from wikipedia

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus

Sign Up to like & get
recommendations!
Published in 2022 at "Frontiers in Medicine"

DOI: 10.3389/fmed.2022.877237

Abstract: Chronic kidney disease (CKD) is a global public health problem, and cardiovascular disease is the most common cause of death in patients with CKD. The incidence and prevalence of cardiovascular events during the early stages… read more here.

Keywords: disease; angiotensin; angiotensin receptor; neprilysin inhibitor ... See more keywords
Photo from wikipedia

Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.

Sign Up to like & get
recommendations!
Published in 2018 at "Cardiology journal"

DOI: 10.5603/cj.a2018.0048

Abstract: BACKGROUND Recent clinical studies have shown that treatment with LCZ696, a complex containing the angiotensin receptor blocker valsartan and neprilysin inhibitor sacubitril, improves the prognosis of heart failure patients with a reduced ejection fraction. This… read more here.

Keywords: fibrosis; iso; angiotensin receptor; neprilysin inhibitor ... See more keywords